 Avalon GloboCare Corp NASDAQ:AVCO has said it is expanding its co-development research program with the Massachusetts Institute of Technology MIT, involving the use of CRISPR-based genome editing and QTY protein design technology to potentially treat and prevent cancer metastasis the spreading of cancer cells from the initial tumor site to surrounding tissues and other organs. The company noted that its collaboration with MIT on the QTY code has already successfully generated a prototype device to soak up the excess chemokines and cytokines produced in the body that lead to a potentially fatal cytokine storm, which can occur in patients with coronavirus COVID-19 and in cancer patients being treated with CAR T-cell therapy. 